So what's that got to do with RVX or Zenith for that matter. In an article in Endpoints News yesterday they talk about bolt-on deals like this to enhance the value of their company. I will put the link to the article at the end. 

Jefferies analyst Michael Yee, who welcomed the reported takeover offer last week, called that data “high efficacy” and said today that the price was “reasonable.” He projected between $800 million and $1 billion in peak sales, in line with other estimates.

“They’re rightfully sticking to their strategy of bolt-ons within their core focus areas,” Yee wrote in a note to investors.  “It bolsters GILD’s focus on immuno-onc and provides a potential first-in-class pipeline within a product to their portfolio.”

The reason I bring this up is that the Jefferies analyst says it was a reasonable price at approximately 5X's potential annual sales and 2 other analyst echoed his comments. One really has to wonder what RVX is worth with potential annual sales in excess of $5 billion if 5X's potential annual sales is a reasonable price. With a patent that currently goes out to 2034. New IP protection was filed for after the results of BETonMACE were received. If we get that, and we should, we could be looking at patent protection until 2040. That's 16 or 17 years of patent protection for any company that may want to enhance their product portfolio with a first in class, safe drug, assuming we get through a NDA process within 3 to 4 years. What's that worth.  

How many companies out there have a cardio, diabetic, or CKD product line that could use a first in class product to enhance their existing product line? The Zenith/PFE TNBC trial is testing ZEN-3694 with their CAR-T drug. Both apabetalone and ZEN-3694 are first in class drugs. We know ABL has a good safety profile and maybe one day we will hear something about ZEN-3694's safety profile. Both of these drugs would make a great bolt-on for an existing product portfolio.

Come on RVX and Zenith, get'er done.

Just some food for thought.

https://endpts.com/gilead-makes-biggest-buy-in-three-years-betting-4-9b-on-dont-eat-me-signal-cancer-biotech/

DYODD

tada